Neuronal apoptosis and motor deficits in mice with genetic inhibition of GSK-3 are Fas-dependent.
Glycogen synthase kinase-3 (GSK-3) inhibitors have been postulated as useful therapeutic tools for the treatment of chronic neurodegenerative and neuropsychiatric diseases. Nevertheless the clinical use of these inhibitors has been limited by their common side effects. Lithium, a non-selective GSK-3 inhibitor has been classically administered to treat bipolar patients but its prescription is decreasing due to its frequent side effects such as hand tremor. This toxicity seems to be higher in the elderly and a clinical trial with lithium for Alzheimer's disease was stopped due to high rate of discontinuation. We have previously described a mechanism for the adverse effects of chronic lithium that involves neuronal apoptosis via Fas signaling. As lithium inhibits many other enzymatic activities such as inositol monophosphatase and histone deacetylase, here we aim to genetically test whether GSK-3 inhibition induces those adverse effects through Fas receptor. For this purpose we took advantage of a transgenic mouse line with decreased GSK-3 activity (Tet/DN-GSK-3 mice) that shows increased rate of neuronal apoptosis as well as motor deficits and brought it to a Fas deficient background (lpr mice). We found that apoptosis induced by GSK-3 inhibition was absent in Fas deficient background. Interestingly, motor deficits were also absent in Fas deficient Tet/DN-GSK-3 mice. These results demonstrate that Fas signaling contributes to the neurological toxicity of GSK-3 inhibition and suggest that a combination of GSK-3 inhibitors with blockers of Fas signaling could help to improve the application of GSK-3 inhibitors to clinics.
Centro de Biología Molecular Severo Ochoa, CSIC/UAM, Madrid, Spain.
Raquel
R
Gómez-Sintes
José J
JJ
Lucas
D000818:Animals; D017209:Apoptosis; D003342:Corpus Striatum / Q000166:cytology / Q000201:enzymology; D020820:Dyskinesias / Q000201:enzymology; D005260:Female; D005625:Frontal Lobe / Q000166:cytology / Q000201:enzymology; D038362:Glycogen Synthase Kinase 3 / Q000235:genetics* / Q000378:metabolism; D008297:Male; D051379:Mice; D008810:Mice, Inbred C57BL; D008822:Mice, Transgenic; D009048:Motor Skills; D009474:Neurons / Q000502:physiology*; D045442:Rotarod Performance Test; D019014:fas Receptor / Q000378:metabolism*
D019014:fas Receptor; D038362:Glycogen Synthase Kinase 3